BILL · 2023–24 SESSION
HB 1356: Biosimilar medicines
Reducing prescription drug costs by eliminating barriers impeding access to biosimilar medicines.
Did not pass Did not pass · died in committee
- IntroducedJan 16, 2023
- Out of committeestopped here
- Passed House
- Passed Senate
- Governor
- Law
- Prime sponsor
- Kristine Reeves (D-30)
- Introduced
- January 16, 2023 in the House
- Last action
- January 8, 2024
- Budget
- Has a fiscal note
AN ACT Relating to reducing prescription drug costs by eliminating barriers impeding access to biosimilar medicines;
Sponsors
Prime sponsor: Kristine Reeves (D-30)
5 co-sponsors (5 Democrats, 0 Republicans)
Votes
No recorded floor votes. This measure never reached a floor vote.
History
- By resolution, reintroduced and retained in present status.
- First reading, referred to Health Care & Wellness.
HB 1356 in other sessions
Bill numbers restart every two years, so the same number is a different bill in each session.
- HB 1356 (2025–26) K-12 funding
- HB 1356 (2021–22) Native American names, etc.
- HB 1356 (2019–20) Peer support group privilege
- HB 1356 (2017–18) Physician limited licenses
- HB 1356 (2015–16) Sick & safe employment leave
- HB 1356 (2013–14) Hearing aids coverage
- HB 1356 (2011–12) Credit card interest rates
- HB 1356 (2009–10) Middle sch student tech edu